Treating Alzheimer’s: Is It Really an Autoimmune Disease?
Although Alzheimer’s is still listed as an incurable neurodegenerative disease, medical science has come a long way in terms of...
Day: October 21, 2022
BriaCell Announces Successful Completion of Phase I Portion of Clinical Study in Advanced Breast Cancer; Randomized Phase II Efficacy Evaluation Progressing
BriaCell has successfully completed its Phase I safety and tolerability evaluation of Bria-IMT™ in combination with Incyte’s retifanlimab in advanced...
Avricore to Present at Emerging Growth Conference on Oct. 26, 2022
VANCOUVER, British Columbia, Oct. 21, 2022 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “AVCR”) is excited to...
Altamira Therapeutics Announces Divestiture of Inner Ear Development Assets
HAMILTON, BERMUDA , Oct. 21, 2022 (GLOBE NEWSWIRE) -- Definitive agreement to sell 90% stake in Company’s Zilentin subsidiary with...
Allied Corp. Announces Completion of First THC Flower Harvests Now Offered for Sale and Export From Colombia
KELOWNA, British Columbia, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) is pleased to...
EPI Health, a Novan Company, and MC2 Therapeutics Announce Data from Survey Conducted by National Psoriasis Foundation Presented at 42nd Annual Fall Clinical Dermatology Conference®
Data collected shows importance of treatment formulation characteristics and speed of improvement in psoriasis symptoms to patient treatment adherenceDURHAM, N.C....
EPI Health, a Novan Company, and MC2 Therapeutics Present New Data In Multiple Posters Highlighting WYNZORA’s® Unique PAD Technology™ at the 42nd Annual Fall Clinical Dermatology Conference®
Research shows PAD (Polyaphron Dispersion) Technology™ leads to more efficient delivery of Calcipotriene (CAL) and Betamethasone Dipropionate (BDP) than CAL/BDP topical...
Obesity Canada Publishes First Update to 2020 Adult Clinical Practice Guidelines
Emerging research captured in revised chapters summarizing evidence for medical nutrition therapy and pharmacotherapyEDMONTON, Alberta, Oct. 21, 2022 (GLOBE NEWSWIRE)...
CinCor Pharma Announces Publication of Phase 1 Multiple Ascending Dose Study Data in Hypertension Research
WALTHAM, Mass., Oct. 21, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced the publication of Phase 1...
Eyenovia to Present at the American Academy of Optometry’s Annual Meeting
NEW YORK, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet®...
Nighthawk Biosciences’ Scorpion Subsidiary Announces Grand Opening of its San Antonio Facility
DURHAM, N.C., Oct. 21, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company focused on developing...
Nationwide Seborrheic Dermatitis Survey Shows Burdensome and Lengthy Path to Diagnosis
Findings presented at the annual Fall Clinical Dermatology ConferenceSurvey found that path to diagnosis for people with seborrheic dermatitis (average...
NeuBase Therapeutics Announces Gene Editing Research Agreement with Global Healthcare Company
PITTSBURGH, Oct. 21, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company...
Microbot Medical Announces $5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
HINGHAM, Mass., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into...
Matinas BioPharma Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203 for the Treatment of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold; Patient Survival in All-Oral Cohort 4 Regimen Currently 90%
Study Design EnACT Phase 2 DesignTwo-week survival in Cohort 4 (all-oral regimen) was 95% in 40 patients receiving MAT2203 Mean...
Sientra Announces Pricing of $13.2 Million Public Offering
SANTA BARBARA, Calif., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics...
Optinose Announces Late Breaking Abstract Podium Presentation at IDWeek 2022
Presentation highlights a greater than 60% reduction in acute exacerbations and need for antibiotics for chronic sinusitis patients who used...
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
Reiterates Quality and Composition of Mereo’s Significantly Refreshed Board, which has the Right Skills and Experience to Guide Mereo’s Strategy...
Matinas BioPharma to Present at the ThinkEquity Annual Global Investment Conference
BEDMINSTER, N.J., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the...
Axsome Therapeutics to Report Third Quarter 2022 Financial Results on November 7, 2022
Axsome to host conference call and webcast on Monday, November 7, 2022 at 8:00 AM Eastern Time NEW YORK, Oct....